ASk1 N-terminal Dimerization Inhibition for Steatohepatitis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nonalcoholic steatohepatitis (NASH) are limited in effectiveness, and there is a need for pharmaceutical compounds that can specifically target and inhibit the N-terminal dimerization of apoptosis signal-regulated kinase 1 (ASK1) to effectively treat the condition.
Innovation Solution
A method and model for screening pharmaceutical compounds using the N-terminal dimerization of ASK1 as a target, involving a CheckMate™ mammalian two-hybrid system and cell models like HEK-293T, L02, and Huh7 cells to identify substances that inhibit ASK1 dimerization, with potential compounds like Peptide1 being overexpressed in liver tissue using adeno-associated virus AAV8 for therapeutic evaluation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatment methods for nonalcoholic steatohepatitis are used, then treatment coverage is provided, but therapeutic effect is very limited
Solution Approach 1:
The invention segments the ASK1 protein into functional domains, specifically targeting the N-terminal region (amino acids 1-239) that mediates dimerization. By designing inhibitors that specifically bind to this segmented region, the patent achieves selective interference with ASK1 activation while preserving other cellular functions, thereby improving therapeutic effectiveness without excessive side effects
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that bind to the N-terminal region of ASK1 and prevent dimerization. These intermediary molecules act as blockers between ASK1 monomers, preventing the formation of active dimers and subsequently inhibiting the downstream signaling cascade that leads to steatohepatitis pathology
2Reliability
If ASK1 activation is inhibited to treat steatohepatitis, then disease progression is slowed, but specific targeting of N-terminal dimerization requires novel screening methods
Solution Approach 1:
The invention extracts the N-terminal region (amino acids 1-239) of ASK1 as a separate functional domain for targeted inhibition. By isolating this specific region that is responsible for dimerization, the patent enables focused drug screening and development efforts on this extracted segment, simplifying the overall drug discovery process while maintaining high specificity
Solution Approach 2:
The patent performs preliminary action by constructing a recombinant N-terminal ASK1 protein and establishing screening assays before actual drug discovery begins. This preparatory work including protein expression system setup and dimerization assay development creates a ready-to-use platform that accelerates subsequent compound screening and reduces overall development complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively inhibits ASK1 dimerization, reducing hepatic steatosis and liver lipid accumulation, thereby mitigating steatohepatitis in cynomolgus monkeys, demonstrating potential as a novel therapeutic strategy for NASH treatment.
Implementation Method 1
potential compounds like Peptide1 being overexpressed in liver tissue using adeno-associated virus AAV8 for therapeutic evaluation
Implementation Method 2
two ASK1 monomers binding to each other through a coiled helix domain located at its N-terminal to form a dimeric polymer
Implementation Method 3
Trx undergoes an oxidation reaction and then dissociates from ASK1, causing the ASK1 N-terminal to form a dimeric polymer
Data Source
AI summary
A method for screening a pharmaceutical compound for prevention, alleviation and/or treatment of steatohepatitis, the method including employing N-terminal dimerization of an apoptosis signal-regulated kinase 1 as a target.